Alzheon
Framingham, MA, United States · Biotechnology · 31 employees
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and
Funding history
- Venture - Series Unknown — $126.3M — Feb 2025
- Venture - Series Unknown — $125.0M — Jan 2025
- Series E — $100.0M — Jun 2024
- Venture - Series Unknown — $17.2M — Mar 2024
- Seed — $1.7M — Jan 2023
Recent signals
- Feb 10, 2025: Raised $126.3M in Venture - Series Unknown
- Jan 07, 2025: Launched Alzheon, Inc. Appoints Muneer A. Satter to Board of Directors to Guide Upcoming Commercialization Efforts.
- Jan 02, 2025: Raised $125.0M in Venture - Series Unknown
- Jun 12, 2024: Raised $100.0M in Series E
- Mar 12, 2024: Raised $17.2M in Venture - Series Unknown
- Jan 11, 2023: Raised $1.7M in Seed
- Apr 14, 2022: Raised $50.0M in Series D
- Sep 30, 2020: Raised $126.3M in Seed
See plans & pricing → Track Alzheon’s funding, hiring, and signals — with verified contacts — on Fundz.